{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:39:42Z","timestamp":1784356782201,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Pharma AG, Basel, Switzerland","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Novartis Pharma AG, Basel, Switzerland","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Novartis Pharma AG, Basel, Switzerland","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Novartis Pharma AG, Basel, Switzerland","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Novartis Pharma AG, Basel, Switzerland","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Novartis Pharma AG, Basel, Switzerland","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Erenumab, a fully human monoclonal antibody that targets the calcitonin gene-related peptide receptor, has demonstrated efficacy and safety in the prevention of episodic and chronic migraine. There exists an unmet need to establish the safety of erenumab in older individuals, in view of existing multiple comorbidities, polypharmacy, and age-related physiological changes. This pooled analysis of five large migraine-prevention studies examined the safety of erenumab stratified across age groups, particularly in older populations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Pooled and age-stratified analysis of safety data from the 12-week double-blind treatment phase (DBTP) of five randomized, placebo-controlled Phase 2 and 3 studies of erenumab in participants with episodic or chronic migraine across the age groups\u2009&lt;\u200940\u00a0years, 40\u201349\u00a0years, 50\u201359\u00a0years, and\u2009\u2265\u200960\u00a0years was completed. The safety of erenumab across age groups was determined by assessing safety endpoints including treatment-emergent adverse events (AEs), serious AEs, and events leading to study drug discontinuation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 3345 participants across five studies were randomized to receive either placebo (<jats:italic>n<\/jats:italic>\u2009=\u20091359), erenumab 70\u00a0mg (<jats:italic>n<\/jats:italic>\u2009=\u20091132) or erenumab 140\u00a0mg (<jats:italic>n<\/jats:italic>\u2009=\u2009854); 3176 (94.9%) completed the DBTP, and 169 (5.1%) discontinued, mainly due to participant decision (110; 3.3%). Overall, 1349 (40.6%), 1122 (33.8%), and 850 (25.6%) participants received at least one dose of placebo, erenumab 70\u00a0mg, and erenumab 140\u00a0mg, respectively.<\/jats:p>\n                <jats:p>Incidence of treatment-emergent AEs was similar across all age groups for both doses of erenumab (70\u00a0mg or 140\u00a0mg) and placebo (&lt;\u200940\u00a0years, 44.0% vs 44.4%; 40\u201349\u00a0years, 42.5% vs 49.2%; 50\u201359\u00a0years, 46.5% vs 41.6%;\u2009\u2265\u200960\u00a0years, 43.8% vs 59.4%). Incidence of treatment-emergent serious AEs overall, and stratified by age groups for both doses and placebo was low (&lt;\u200940\u00a0years, 0.9% vs 1.2%; 40\u201349\u00a0years, 1.7% vs 1.9%; and 50\u201359\u00a0years, 1.6% vs 1.1%), with no serious AEs reported in participants aged\u2009\u2265\u200960\u00a0years. No deaths were reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Erenumab (70\u00a0mg or 140\u00a0mg) exhibited a similar safety profile compared with placebo across age groups in individuals with episodic or chronic migraine, with no increased emergence of events due to age. Erenumab was well tolerated in older participants with multiple comorbidities, polypharmacy, and age-related physiological changes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration number<\/jats:title>\n                <jats:p>ClinicalTrials.gov Identifiers: NCT02066415, NCT02456740, NCT02483585, NCT03096834, NCT03333109.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-022-01470-4","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:02:43Z","timestamp":1660780963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1756-1181","authenticated-orcid":false,"given":"Christian","family":"Lampl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Lehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Loop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahan","family":"Chehrenama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"Maczynska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Klatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefin","family":"Snellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"issue":"3","key":"1470_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11916-006-0047-6","volume":"10","author":"ME Bigal","year":"2006","unstructured":"Bigal ME, Lipton RB (2006) Migraine at all ages. Curr Pain Headache Rep 10(3):207\u2013213","journal-title":"Curr Pain Headache Rep"},{"issue":"10100","key":"1470_CR2","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"T Vos","year":"2017","unstructured":"Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F et al (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet 390(10100):1211\u20131259","journal-title":"The Lancet"},{"issue":"11","key":"1470_CR3","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"LJ Stovner","year":"2018","unstructured":"Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM et al (2018) Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology 17(11):954\u2013976","journal-title":"The Lancet Neurology"},{"issue":"10283","key":"1470_CR4","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, \u00d6zge A et al (2021) Migraine: epidemiology and systems of care. The Lancet 397(10283):1485\u20131495","journal-title":"The Lancet"},{"issue":"1\u20132","key":"1470_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1159\/000494758","volume":"52","author":"T Wijeratne","year":"2019","unstructured":"Wijeratne T, Tang HM, Crewther D, Crewther S (2019) Prevalence of migraine in the elderly: a narrated review. Neuroepidemiology 52(1\u20132):104\u2013110","journal-title":"Neuroepidemiology"},{"issue":"2","key":"1470_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1468-2982.2006.01250.x","volume":"27","author":"J Haan","year":"2007","unstructured":"Haan J, Hollander J, Ferrari MD (2007) Migraine in the elderly: a review. Cephalalgia 27(2):97\u2013106","journal-title":"Cephalalgia"},{"issue":"4","key":"1470_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1056\/NEJMra010917","volume":"346","author":"PJ Goadsby","year":"2002","unstructured":"Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine\u2014current understanding and treatment. N Engl J Med 346(4):257\u2013270","journal-title":"N Engl J Med"},{"issue":"3","key":"1470_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1474-4422(10)70005-3","volume":"9","author":"PJ Goadsby","year":"2010","unstructured":"Goadsby PJ, Sprenger T (2010) Current practice and future directions in the prevention and acute management of migraine. The Lancet Neurology 9(3):285\u2013298","journal-title":"The Lancet Neurology"},{"issue":"6","key":"1470_CR9","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35(6):478\u2013488","journal-title":"Cephalalgia"},{"issue":"3","key":"1470_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/WCO.0b013e32836085f4","volume":"26","author":"A Charles","year":"2013","unstructured":"Charles A (2013) Migraine: a brain state. Curr Opin Neurol 26(3):235\u2013239","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"1470_CR11","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s40265-018-0944-0","volume":"78","author":"A Markham","year":"2018","unstructured":"Markham A (2018) Erenumab: first global approval. Drugs 78(11):1157\u20131161","journal-title":"Drugs"},{"issue":"1","key":"1470_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1124\/jpet.115.227793","volume":"356","author":"L Shi","year":"2016","unstructured":"Shi L, Lehto SG, Zhu DX, Sun H, Zhang J, Smith BP et al (2016) Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther 356(1):223\u2013231","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"1470_CR13","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V et al (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38(6):1026\u20131037","journal-title":"Cephalalgia"},{"issue":"10161","key":"1470_CR14","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. The Lancet 392(10161):2280\u20132287","journal-title":"The Lancet"},{"issue":"6","key":"1470_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein S et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Neurology 16(6):425\u2013434","journal-title":"The Lancet Neurology"},{"issue":"13","key":"1470_CR16","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1177\/03331024211024160","volume":"41","author":"S-J Wang","year":"2021","unstructured":"Wang S-J, Roxas AA Jr, Saravia B, Kim B-K, Chowdhury D, Riachi N et al (2021) Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study. Cephalalgia 41(13):1285\u20131297","journal-title":"Cephalalgia"},{"issue":"22","key":"1470_CR17","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F et al (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377(22):2123\u20132132","journal-title":"N Engl J Med"},{"issue":"5","key":"1470_CR18","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"M Ashina","year":"2021","unstructured":"Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F et al (2021) Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28(5):1716\u20131725","journal-title":"Eur J Neurol"},{"issue":"5","key":"1470_CR19","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1212\/WNL.0000000000008743","volume":"94","author":"D Kudrow","year":"2020","unstructured":"Kudrow D, Pascual J, Winner PK, Dodick DW, Tepper SJ, Reuter U et al (2020) Vascular safety of erenumab for migraine prevention. Neurology 94(5):e497\u2013e510","journal-title":"Neurology"},{"issue":"14","key":"1470_CR20","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1177\/0333102419888222","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ et al (2019) Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: a pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia 39(14):1798\u20131808","journal-title":"Cephalalgia"},{"key":"1470_CR21","volume-title":"ICH Topic E 9: Statistical Principles for Clinical Trials","author":"C Ich","year":"2006","unstructured":"Ich C (2006) ICH Topic E 9: Statistical Principles for Clinical Trials. EMEA (European Medicines Agengy), London"},{"key":"1470_CR22","volume-title":"US Prescribing Information","author":"AIMOVIG injection fsu","year":"2018","unstructured":"AIMOVIG injection fsu (2018) US Prescribing Information"},{"key":"1470_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/B978-0-12-804766-8.00028-5","volume":"167","author":"RG Kaniecki","year":"2019","unstructured":"Kaniecki RG, Levin AD (2019) Headache in the elderly. Handb Clin Neurol 167:511\u2013528","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"1470_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1124\/pr.56.2.4","volume":"56","author":"AJ McLean","year":"2004","unstructured":"McLean AJ, Le Couteur DG (2004) Aging biology and geriatric clinical pharmacology. Pharmacol Rev 56(2):163\u2013184","journal-title":"Pharmacol Rev"},{"issue":"1","key":"1470_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12877-022-03027-1","volume":"22","author":"M Togha","year":"2022","unstructured":"Togha M, Karimitafti MJ, Ghorbani Z, Farham F, Naderi-Behdani F, Nasergivehchi S et al (2022) Characteristics and comorbidities of headache in patients over 50 years of age: a cross-sectional study. BMC Geriatr 22(1):313","journal-title":"BMC Geriatr"},{"issue":"4","key":"1470_CR26","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","volume":"94","author":"FA Russell","year":"2014","unstructured":"Russell FA, King R, Smillie SJ, Kodji X, Brain SD (2014) Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 94(4):1099\u20131142","journal-title":"Physiol Rev"},{"issue":"2","key":"1470_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40259-021-00469-8","volume":"35","author":"M Sessa","year":"2021","unstructured":"Sessa M, Andersen M (2021) New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database. BioDrugs 35(2):215\u2013227","journal-title":"BioDrugs"},{"key":"1470_CR28","unstructured":"AimovigTM (INN-erenumab) European Medicines Agency. Summary of Product Characteristics. Available at: https:\/\/www.emaeuropaeu\/en\/documents\/product-information\/aimovig-epar-product-information-enpdf. Accessed Aug\u00a02022"},{"key":"1470_CR29","doi-asserted-by":"publisher","unstructured":"Liang D, Sessa M (2022) Post-marketing safety surveillance of erenumab: new insight from Eudravigilance. Expert Opin Drug Saf 1\u20136. https:\/\/doi.org\/10.1080\/14740338.2022.2049231. Epub ahead of print","DOI":"10.1080\/14740338.2022.2049231"},{"issue":"7","key":"1470_CR30","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/phar.2706","volume":"42","author":"J Perino","year":"2022","unstructured":"Perino J, Corand V, Laurent E, Theophile H, Miremont-Salame G, Pariente A et al (2022) Myocardial infarction associated with erenumab: A case report. Pharmacotherapy 42(7):585\u2013589","journal-title":"Pharmacotherapy"},{"issue":"1","key":"1470_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01213-3","volume":"22","author":"TR Smith","year":"2021","unstructured":"Smith TR, Spierings EL, Cady R, Hirman J, Schaeffler B, Shen V et al (2021) Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. J Headache Pain 22(1):1\u201311","journal-title":"J Headache Pain"},{"issue":"6","key":"1470_CR32","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/head.13534","volume":"59","author":"SD Silberstein","year":"2019","unstructured":"Silberstein SD, McAllister P, Ning X, Faulhaber N, Lang N, Yeung P et al (2019) Safety and tolerability of fremanezumab for the prevention of migraine: a pooled analysis of phases 2b and 3 clinical trials. Headache: J Head and Face Pain 59(6):880\u201390","journal-title":"Headache: J Head and Face Pain"},{"issue":"1","key":"1470_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s10194-021-01351-2","volume":"22","author":"SJ Nahas","year":"2021","unstructured":"Nahas SJ, Naegel S, Cohen JM, Ning X, Janka L, Campos VR et al (2021) Efficacy and safety of fremanezumab in clinical trial participants aged >\/=60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies. J Headache Pain 22(1):141","journal-title":"J Headache Pain"},{"issue":"11","key":"1470_CR34","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1007\/s12325-021-01911-7","volume":"38","author":"U Reuter","year":"2021","unstructured":"Reuter U, Lucas C, Dolezil D, Hand AL, Port MD, Nichols RM et al (2021) Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial. Adv Ther 38(11):5465\u20135483","journal-title":"Adv Ther"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01470-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-022-01470-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-022-01470-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:02:52Z","timestamp":1660780972000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01470-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1470"],"URL":"https:\/\/doi.org\/10.1186\/s10194-022-01470-4","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"assertion":[{"value":"22 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval for each study was provided by the Independent Ethics Committee or Institutional Review Board of the study sites. The list of the IEC or IRB for each study has been provided in the Additional file . The studies were conducted in accordance with Good Clinical Practice guidelines, the principles of the Declaration of Helsinki, and all applicable regulatory requirements. Participants provided written informed consent prior to initiation of any study procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Christian Lampl received honoraria from Novartis for given lectures and his participation in Advisory Board Meetings.Victoria Krauss declares that they have no competing interests.Katharina Lehner declares that they have no competing interests.Mahan Chehrenama is an employee of, and holds stock in Amgen Inc.Zofia Maczynska is a former employee of Novartis.Jan Klatt is a former employee of, and holds stock in Novartis.Brett Loop was an employee of Amgen Inc., US at the time of study conduct.Brett Loop, Shannon Ritter and Josefin Snellman are employees of, and hold stocks in Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}